Company Overview and News

 
Suspension - Nyota Minerals Limited

2017-08-17 londonstockexchange
Trading on AIM for the under-mentioned securities has been temporarily suspended from 17/08/2017 7:30am, pursuant to AIM Rule 1.
Upvote Downvote

 
Q2 and HY 2017 Results and Interim Dividend

2017-08-03 londonstockexchange
Centamin plc ("Centamin", the "Group" or "the Company") (LSE: CEY, TSX: CEE) is pleased to announce its results for the second quarter ended 30 June 2017.
Upvote Downvote

 
Quarterly Report

2017-07-20 londonstockexchange
Nyota Minerals Limited (ASX/AIM: NYO) provides its Quarterly Report for the three months ended 30 June 2017.
Upvote Downvote

 
Result of General Meeting and Company update

2017-07-03 londonstockexchange
In accordance with ASX Listing Rule 3.13.2, the following resolutions were voted on by show of hands or poll, as indicated below, by shareholders at the General Meeting of Nyota Minerals Limited (Nyota or Company) held at 10:30am (Sydney time) on Monday 3 July 2017 (Meeting). Resolution 1 (Appointment of Mr James Patrick Normand as a Director) and Resolution 6 (Authority to issue Shares) were ultimately withdrawn from consideration at the Meeting.
Upvote Downvote

 
Share Price Movement

2017-05-11 londonstockexchange
The Board of Nyota Minerals Limited (ASX/AIM: NYO) notes the recent rise in the Company's share price and trading volumes and advises that other than the matters announced on 3 May 2017 in connection with, inter alia, the placing, it is not aware of any specific reason for such movement and volumes.
Upvote Downvote

 
Q1 2017 Results

2017-05-03 londonstockexchange
Centamin plc ("Centamin", the "Group" or "the Company") (LSE: CEY, TSX: CEE) is pleased to announce its results for the first quarter ended 31 March 2017.
Upvote Downvote

 
Holding(s) in Company

2017-04-13 londonstockexchange
The Board of Nyota Minerals Limited (ASX/ AIM: NYO) announces that on 13 April 2017 the Company was informed that Mark Lancaster no longer had a notifiable interest in the Company.
Upvote Downvote

 
Quarterly Report

2017-04-07 londonstockexchange
Nyota Minerals Limited (ASX/AIM: NYO) provides its Quarterly Report for the three months ended 31 March 2017.
Upvote Downvote

 
Company Secretary Change

2017-04-06 londonstockexchange
The Board of Nyota Minerals Limited announces the resignation of Michael Langoulant as Company Secretary and the appointment of Andrew Wright as Company Secretary.
Upvote Downvote

 
Result of EGM

2017-04-05 londonstockexchange
In accordance with ASX Listing Rule 3.13.2, the following resolution was passed on a show of hands by shareholders at the adjourned Extraordinary General Meeting of Nyota Minerals Limited held on Tuesday 4 April 2017.
Upvote Downvote

 
Holding(s) in Company

2017-03-21 londonstockexchange
The Board of Nyota Minerals Limited (ASX/ AIM: NYO) announces that on 21 March 2017 the Company received the following TR-1 notification which is set out below without material amendment:
Upvote Downvote

 
Restoration - Nyota Minerals Limited

2017-03-16 londonstockexchange
The trading on AIM for the under-mentioned securities was temporarily suspended. The suspension is lifted from 16/03/2017 7:30am, an announcement having been made.
Upvote Downvote

 
Notice of GM

2017-02-17 londonstockexchange
Nyota Minerals Limited (ASX/AIM: NYO) has today published a notice of Extraordinary General Meeting (Meeting) to be held at 5:30pm (Sydney time) on 21 March 2017 at the Offices of Norton Rose Fulbright, Level 18, Grosvenor Place, 225 George Street, Sydney NSW 2000, Australia (Notice).
Upvote Downvote

 
Half-year Report

2017-02-15 londonstockexchange
Nyota Minerals Limited (ASX/AIM: NYO) announces its reviewed half yearly report (the "Report") for the six months ended 31 December 2016.
Upvote Downvote

 
Annual results for the year ended 31 December 2016

2017-02-01 londonstockexchange
Josef El-Raghy, Chairman of Centamin, commented: "During 2016 Centamin's flagship Sukari Gold Mine continued to deliver substantial free cash flows, driven by a seventh successive year of production growth and through reductions in operating costs. This performance has allowed Centamin to maintain its strategic focus on generating shareholder returns and value-accretive growth. A significant milestone was achieved during the year, as the capital investment in the Sukari operation by Centamin's wholly-owned subsidiary Pharaoh Gold Mines ("PGM") was recovered from cash flows to the extent that profit share commenced with the Egyptian Government during the third quarter.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...